Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
56.12
+0.65 (1.17%)
Jul 21, 2026, 12:48 PM EDT - Market open
Travere Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Travere Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $58.36. The average 1-year stock price forecast is 3.99% higher than the current stock price, while the lowest is $43 (-23.38%) and the highest is $70 (+24.73%).
Price Target: $58.36 (+3.99%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 12 | 12 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $56 | Buy | Maintains | $56 | -0.21% | Jul 8, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $56 → $65 | Buy | Reiterates | $56 → $65 | +15.82% | Jun 25, 2026 |
| Wedbush | Wedbush | Buy Maintains $55 → $61 | Buy | Maintains | $55 → $61 | +8.70% | Jun 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $67 | Buy | Reiterates | $67 | +19.39% | Jun 22, 2026 |
| Citi | Citi | Buy Reiterates $62 → $70 | Buy | Reiterates | $62 → $70 | +24.73% | Jun 15, 2026 |
Financial Forecast
Revenue This Year
697.77M
from 490.73M
Increased by 42.19%
Revenue Next Year
968.88M
from 697.77M
Increased by 38.85%
EPS This Year
1.87
from 0.91
Increased by 105.34%
EPS Next Year
4.85
from 1.87
Increased by 159.59%
EPS and Forward PE are based on non-GAAP adjusted numbers.